Stifel raised the firm’s price target on ClearPoint Neuro to $9 from $8 and keeps a Buy rating on the shares. ClearPoint “garnered considerable momentum in 2024” and while quarterly results are still likely to fluctuate, the path forward is “increasingly compelling with high, sustainable growth and improved profitability,” the analyst tells investors in a post-earnings note, citing lower regulatory risk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLPT:
- ClearPoint Neuro Unveils Insightful Investor Presentation Update
- ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
- ClearPoint Neuro announces publication on Prism Neuro Laser Therapy System
- ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
- ClearPoint Neuro 2.31M share Spot Secondary priced at $6.50
